查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417482

藥物基因體學技術市場報告：至2030年的趨勢、預測與競爭分析

Pharmacogenomics Technology Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

藥物基因體學技術趨勢與預測

預計到2030年，全球藥物基因體學技術市場將達到 124 億美元，2024年至2030年年複合成長率為 6.7%。該市場的主要驅動力是基因組學領域在闡明遺傳差異及其對藥物反應性影響方面的重大進展，由於慢性病患病率增加而日益增加的個性化治療需求，基因組序列測定成本的下降以及技術的進步。全球藥物基因體學技術市場的未來看起來充滿希望，腫瘤學、神經學、循環系統、免疫學和感染疾病市場都有機會。

藥物基因體學技術市場洞察

Lucintel認為，由於PCR可以擴增特定的DNA序列，因此它是基因分型和確定與藥物反應相關的遺傳變異的重要工具，PCR是基因分型和確定與藥物反應相關的遺傳變異的重要工具。因經常用於發現影響藥物功效和代謝的遺傳變化和單核苷酸多態性 (SNP)，預計在預測期內仍將是最大的細分市場。

由於該行業知名公司的存在、有利的保險償付規則、人們日益認知到早期診斷對改善治療的重要性以及該地區發達的醫療基礎設施，預計北美在預測期內仍將是最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，全球藥物基因體學技術市場預計將達到124億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球藥物基因體學技術市場預計將以6.7%的年複合成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要驅動力是基因組學領域在了解遺傳差異及其對藥物反應性影響方面的重大進展、由於慢性病數量不斷增加而對個性化治療的需求不斷成長，以及序列測定。這些是成本降低和技術進步。

Q4.市場的主要細分市場是什麼？

A4.全球藥物基因體學技術市場前景廣闊，腫瘤、神經疾病、循環系統疾病、免疫疾病、感染疾病等市場機會龐大。

Q5.市場上主要企業有哪些？

A5.主要藥物基因體學技術公司如下。

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Q6.未來最大的細分市場是什麼？

A6.Lucintel認為PCR可以擴增特定的DNA序列，是基因分型和確定與藥物反應相關的遺傳變異的重要工具，PCR可以擴增特定的DNA序列，是基因分型和確定的重要工具與藥物反應相關的遺傳變異。預期它在預測期內仍將是最大的區隔，因為經常用於查找類型（SNP）。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於該領域知名公司的存在、有利的償付規則、人們日益認知到早期診斷以改善治療的重要性以及該領域發達的醫療基礎設施，預計北美市場將是一個疲軟的市場。預計在此期間仍將是最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球藥物基因體學技術市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球藥物基因體學技術市場趨勢（2018-2023）與預測（2024-2030）
  • 依技術分類的全球藥物基因體學技術市場
    • PCR
    • 原位雜合反應
    • 免疫組織化學
    • 順序
    • 其他
  • 依治療領域分類的全球藥物基因體學技術市場
    • 瘤
    • 神經系統疾病
    • 循環系統疾病
    • 免疫疾病
    • 感染疾病
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球藥物基因體學技術市場（依地區）
  • 北美藥物基因體學技術市場
  • 歐洲藥物基因體學技術市場
  • 亞太藥物藥物基因體學技術市場
  • 其他地區藥物基因體學技術市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球藥物基因體學技術市場成長機會（依技術）
    • 全球藥物基因體學技術市場成長機會（依治療領域）
    • 全球藥物基因體學技術市場成長機會（依地區）
  • 全球藥物基因體學技術市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球藥物基因體學技術市場的產能擴張
    • 全球藥物基因體學技術市場的合併、收購與合資
    • 認證和許可

第7章 主要企業概況

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer
簡介目錄

Pharmacogenomics Technology Trends and Forecast

The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

A more than 150-page report is developed to help in your business decisions.

Pharmacogenomics Technology by Segment

The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.

Pharmacogenomics Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • PCR
  • In-Situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technology Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Pharmacogenomics Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Pharmacogenomics Technology Market Insights

Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Features of the Global Pharmacogenomics Technology Market

Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).

Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the pharmacogenomics technology market size?

Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.

Q2. What is the growth forecast for pharmacogenomics technology market?

Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?

Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

Q4. What are the major segments for pharmacogenomics technology market?

Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.

Q5. Who are the key pharmacogenomics technology market companies?

Answer: Some of the key pharmacogenomics technology companies are as follows.

  • GE HealthCare
  • Agilent Technologies
  • F. Hoffmann-La Roche
  • FOUNDATION MEDICINE
  • Thermo Fisher Scientific
  • Leica Biosystems Nussloch
  • Pfizer

Q6. Which pharmacogenomics technology market segment will be the largest in future?

Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the pharmacogenomics technology market by technology (PCR, in-situ hybridization, immunohistochemistry, sequencing, and others), therapeutic area (oncology, neurological disorders, cardiovascular disease, immunological disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pharmacogenomics Technology Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Pharmacogenomics Technology Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Pharmacogenomics Technology Market by Technology
    • 3.3.1: PCR
    • 3.3.2: In-situ Hybridization
    • 3.3.3: Immunohistochemistry
    • 3.3.4: Sequencing
    • 3.3.5: Others
  • 3.4: Global Pharmacogenomics Technology Market by Therapeutic Area
    • 3.4.1: Oncology
    • 3.4.2: Neurological Disorders
    • 3.4.3: Cardiovascular Disease
    • 3.4.4: Immunological Disorders
    • 3.4.5: Infectious Diseases
    • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Pharmacogenomics Technology Market by Region
  • 4.2: North American Pharmacogenomics Technology Market
    • 4.2.2: North American Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.3: European Pharmacogenomics Technology Market
    • 4.3.1: European Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.3.2: European Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.4: APAC Pharmacogenomics Technology Market
    • 4.4.1: APAC Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.4.2: APAC Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others
  • 4.5: ROW Pharmacogenomics Technology Market
    • 4.5.1: ROW Pharmacogenomics Technology Market by Technology: PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, and Others
    • 4.5.2: ROW Pharmacogenomics Technology Market by Therapeutic Area: Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Pharmacogenomics Technology Market by Technology
    • 6.1.2: Growth Opportunities for the Global Pharmacogenomics Technology Market by Therapeutic Area
    • 6.1.4: Growth Opportunities for the Global Pharmacogenomics Technology Market by Region
  • 6.2: Emerging Trends in the Global Pharmacogenomics Technology Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Pharmacogenomics Technology Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pharmacogenomics Technology Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: GE HealthCare
  • 7.2: Agilent Technologies
  • 7.3: F. Hoffmann-La Roche
  • 7.4: FOUNDATION MEDICINE
  • 7.5: Thermo Fisher Scientific
  • 7.6: Leica Biosystems Nussloch
  • 7.7: Pfizer